本帖最后由 老马 于 2013-3-13 13:43 编辑 & r" E6 u+ n: e
7 P, h" ~0 J/ T3 `( y& I0 O) q9 o
健择(吉西他滨)+顺铂+阿瓦斯汀/ w/ ^; ~9 I1 ?' ~# L
Gemzar +Cisplatin + Avastin
9 i5 M! |# r* s' ^+ \http://annonc.oxfordjournals.org/content/21/9/1804.full
; C; p7 l7 w4 V o! x* XOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
3 l' c& n0 @6 a+ BPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 2 m) H- @8 l, f; z8 r
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
' e' ~1 T, m( ~
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 196)
2 [/ ~8 z4 {6 ^8 i+ A6 C1 Q p
华为网盘附件:
, |7 T6 L N7 z9 ^' m# ?: r# `' g5 Q【华为网盘】ava.JPG
& P7 J1 R" k7 u4 [6 F |